Clinical Trial Detail

NCT ID NCT03749187
Title BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of California, San Francisco
Indications

glioblastoma multiforme

malignant glioma

Therapies

Pamiparib + Temozolomide

Age Groups: adult child

Additional content available in CKB BOOST